BioSentinel
ApprovedBioSentinel, Inc. develops innovative tools and reagents for the study of botulinum neurotoxin (BoNT).
Founded
2007
Focus
OncologyImmunology
About
BioSentinel, Inc. develops innovative tools and reagents for the study of botulinum neurotoxin (BoNT).
Funding History
6Total raised: $2.2M
Grant$346KNIAIDJul 11, 2013
Grant$346KNIAIDJul 27, 2012
Grant$681KNIAIDJul 8, 2011
Grant$212KNIAIDJan 11, 2011
Company Info
TypePrivate
Founded2007
LocationSan Diego, United States
StageApproved
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile